* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination Please share
Survey
Document related concepts
Immunoprecipitation wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Gluten immunochemistry wikipedia , lookup
Herd immunity wikipedia , lookup
DNA vaccination wikipedia , lookup
Hepatitis B wikipedia , lookup
Henipavirus wikipedia , lookup
Myasthenia gravis wikipedia , lookup
Guillain–Barré syndrome wikipedia , lookup
Molecular mimicry wikipedia , lookup
Vaccination policy wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
HIV vaccine wikipedia , lookup
Vaccination wikipedia , lookup
Immunocontraception wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Anti-nuclear antibody wikipedia , lookup
Transcript
Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Mata-Fink, J et al. “Engineered Gp120 Immunogens That Elicit VRC01-like Antibodies by Vaccination.” Retrovirology 9.Suppl 2 (2012): P6. As Published http://dx.doi.org/10.1186/1742-4690-9-s2-p6 Publisher Biomed Central Ltd. Version Final published version Accessed Fri May 27 00:37:38 EDT 2016 Citable Link http://hdl.handle.net/1721.1/76651 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/2.0 Mata-Fink et al. Retrovirology 2012, 9(Suppl 2):P6 http://www.retrovirology.com/content/9/S2/P6 POSTER PRESENTATION Open Access Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination J Mata-Fink*, M Hanson, B Kriegsman, D Irvine, K Wittrup From AIDS Vaccine 2012 Boston, MA, USA. 9-12 September 2012 Background One of the great challenges for an HIV vaccine is to elicit broadly neutralizing antibodies specific for conserved epitopes from which the virus cannot easily escape. The CD4 binding site is one such epitope against which several antibodies (e.g. b12, VRC01) have been isolated. In macaques infected with SHIV, passive immunization with these CD4-directed neutralizing antibodies fails to control the virus, but prophylactic administration is highly protective. Similarly, patients who generate neutralizing antibodies over the course of an HIV infection derive no clinical benefit from them, but eliciting such antibodies prophylactically by vaccination may prevent the virus from establishing its lethal foothold. Methods Yeast surface display is a powerful method for rapidly engineering complex glycoproteins. We have developed a stripped core gp120 that presents a functional CD4 binding site when displayed on yeast, and an accompanying suite of tools with which to map conformational epitopes of neutralizing antibodies, design novel immunogens, and monitor the specificity of serum following immunization. Results We map the epitopes of the anti-gp120 antibodies VRC01, b12, and b13, and uncover subtle energetic differences in their nearly-overlapping epitopes that are not obvious from existing crystal structures. With this information, we design novel gp120 immunogens that share the VRC01 epitope but whose other surface amino acids are highly diverse. When mice are immunized with these immunogens in a heterologous prime-boost format they elicit VRC01-competitive antibodies and not the competing immunodominant specificities seen with a single immunogen. The antisera are tested for their binding to a panel of gp120, and their neutralization potential is assayed. Conclusion We have engineered a novel set of immunogens that elicit CD4 binding site-directed antibodies upon immunization. The yeast display tools may be used to design future immunogens. Published: 13 September 2012 doi:10.1186/1742-4690-9-S2-P6 Cite this article as: Mata-Fink et al.: Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination. Retrovirology 2012 9(Suppl 2): P6. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit Massachusetts Institute of Technology, Cambridge, MA, USA © 2012 Mata-Fink et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.